1. The Problem

Peripheral neuropathy is a serious complication of diabetes, affecting up to 66% of diabetic patients. This condition can lead to undetected injuries, infections, foot ulcers, gangrene, and, in severe cases, amputations.

Currently, available diagnostic methods—such as the monofilament test, vibration perception test, and nerve conduction studies—are primarily clinic-based. These tests require trained medical personnel and are not accessible for frequent monitoring. There is no convenient, affordable, and user-friendly tool available for patients to self-monitor their nerve health at home. That's where our solution comes in.

2. Our Solution

We propose a biosensor system that uses quantum dots for non-invasive, real-time monitoring of nerve health.

This solution consists of a microneedle patch that injects graphene QDs into the dorsolateral aspect of the great toe. These quantum dots selectively bind to Aδ and C nerve fibers and emit near-infrared light when excited. The intensity of this emitted light corresponds to the condition of the nerves: high intensity indicates healthy nerves, while low intensity suggests nerve damage.

A wearable device equipped with a photodiode detects the light signal and transmits the data to a mobile application. The app provides real-time alerts and prompts the user to consult a doctor if early signs of neuropathy are detected.

3. Comparison with Existing Solutions

Current Methods

Existing diagnostic tests for diabetic neuropathy require trained medical personnel and can be performed only in clinical settings. Procedures like nerve conduction studies are costly, ranging from ₹2000 to ₹6000, and do not offer real-time feedback to patients.

Our Solution

Our biosensor offers a user-friendly alternative that can be used by patients themselves at home. It enables detection of early nerve damage and provides instant results through a mobile app. With a one-time cost of approximately ₹810, the device is portable, affordable, and accessible. Real-time alerts empower patients to take timely action and seek medical attention before the condition worsens.

4. What’s Next

To bring this technology to market, we plan to undertake the following steps:

• Prototype refinement: Develop a PCB-based version of the device, develop the UI of the mobile app.
• Clinical validation: Trials for accuracy and usability in target populations.
• Regulatory approval: Obtain certification as a medical device to ensure compliance with healthcare regulations.
• Scaling and outreach: Pursue partnerships with diabetes clinics and public health programs.
• Accessibility: Translate the mobile app interface into regional languages to enhance accessibility across regions.

Expansion Opportunities

In the future, this technology can be adapted for other conditions such as chemotherapy-induced peripheral neuropathy and age-related sensory loss. This broader application can help improve the quality of life for a wider range of patients through early detection and proactive care.

Built With

• na